pharmaphorum1mon
Galderma adds new indication for blockbuster hope Nemluvio
Dermatology specialist Galderma has claimed a second FDA approval ... like Almirall's Ebglyss (lebrikizumab) and Leo Pharma's Adtralza (tralokinumab), both IL-13 inhibitors, and a clutch of ...
pharmaphorum5mon
Galderma gets FDA nod for prurigo nodularis therapy
Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...
‘Ozempic face’ drives surge in sale of cosmetic fillers
Users of weight-loss drugs are seeking help from dermatologists to rectify ‘facial sagging’ after shedding the pounds ...
Business Wire1mon
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...
Seeking Alpha3d
GALDY Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including ...
Financial Post1mon
Galderma's Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
9,10 Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd., and subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. In Japan, nemolizumab is marketed as ...